ghadmin
Guardant Health Releases Inaugural ESG Report
The publication of its inaugural Environmental, Social & Governance (ESG) Report, which provides information related to key ESG commitments that the company has laid out as part of its business strategy
Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield™ blood test
Shield ™ blood test achieved overall 83% sensitivity and 90% specificity and demonstrated early-stage detection in range with other guideline-recommended non-invasive CRC screening modalities
Guardant Health Announces Additions to Leadership Team
At Guardant, we have built one of the most transformative platforms in diagnostics and we think extensively about how we get work done more efficiently, from development through delivery, to fulfill our primary mission of helping patients
Why 80% in Every Community Matters
During my first semester in college, I took one of the most difficult exams of my life thus far. As my professor passed back our graded tests, he mentioned the average was 90%. But when he handed me my exam – my heart sank as I realized I received a 68% – a ‘D’. In a class of hundreds of students, I felt isolated, while most of my colleagues celebrated. Although the 90% average was an important way of representing the class data, it did not tell the whole story – particularly, the story of individuals such as myself who did not do well. This concept is not just seen in school – it can also be seen in other areas, such as in healthcare.
Guardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response
Project will identify genomic and epigenomic biomarkers in patient blood samples from PICI’s RADIOHEAD study using GuardantINFINITY™
Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer
The data from the pivotal ECLIPSE Study accepted as a late-breaking abstract highlights the performance of the Shield ™ blood test in detecting colorectal cancer in asymptomatic patients
Guardant Health to Report First Quarter 2023 Financial Results on May 9, 2023
Live audio of the webcast will be available on the “Investors” section of the company website. The webcast will be archived and available for replay after the event.
Guardant Health Receives Medicare Coverage for Guardant360 Response™ to Monitor Cancer Patient Response to Immunotherapy
First blood-only liquid biopsy test for monitoring molecular response to immune checkpoint inhibitors now covered for US Medicare patients with metastatic or inoperable solid tumors
Patients Don’t Want Colonoscopies – Let’s Give Them Something Better
The life-saving potential of alternative screening methods for colorectal cancer
Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting
New research demonstrates value of epigenomic analysis and methylation sequencing capabilities of GuardantINFINITY™ platform for biomarker discovery, therapy selection and response monitoring